NMDA receptor

, which modulates receptor function when bound to a ligand, is not occupied.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 24 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

, which modulates receptor function when bound to a ligand, is not occupied. NMDARs require the binding of two molecules of glutamate or aspartate and two of glycine The N-methyl- D -aspartate receptor (also known as the NMDA receptor or NMDAR) is a glutamate receptor and a predominantly Ca 2+ ion channel found in neurons.

The NMDA receptor is one of three types of ionotropic glutamate receptors, the other two being AMPA and kainate receptors. Depending on its subunit composition, its ligands are glutamate and glycine (or D -serine).

However, the binding of the ligands is typically not sufficient to open the channel as it may be blocked by Mg 2+ ions which are only removed when the neuron is sufficiently depolarized. Thus, the channel acts as a "coincidence detector" and only once both of these conditions are met, the channel opens and it allows positively charged ions (cations) to flow through the cell membrane.

The NMDA receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions. The NMDA receptor is ionotropic, meaning it is a protein which allows the passage of ions through the cell membrane.

The NMDA receptor is so named because the agonist molecule N-methyl- D -aspartate (NMDA) binds selectively to it, and not to other glutamate receptors.…

, which modulates receptor function when bound to a ligand, is not occupied. NMDARs require the binding of two molecules of glutamate or aspartate and two of glycine The N-methyl- D -aspartate receptor (also known as the NMDA receptor or NMDAR) is a glutamate receptor and a predominantly Ca 2+ ion channel found in neurons.

The NMDA receptor is one of three types of ionotropic glutamate receptors, the other two being AMPA and kainate receptors. Depending on its subunit composition, its ligands are glutamate and glycine (or D -serine).

However, the binding of the ligands is typically not sufficient to open the channel as it may be blocked by Mg 2+ ions which are only removed when the neuron is sufficiently depolarized. Thus, the channel acts as a "coincidence detector" and only once both of these conditions are met, the channel opens and it allows positively charged ions (cations) to flow through the cell membrane.

The NMDA receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions. The NMDA receptor is ionotropic, meaning it is a protein which allows the passage of ions through the cell membrane.

The NMDA receptor is so named because the agonist molecule N-methyl- D -aspartate (NMDA) binds selectively to it, and not to other glutamate receptors. Activation of NMDA receptors results in the opening of the ion channel that is nonselective to cations, with a combined reversal potential near 0 mV.

While the opening and closing of the ion channel is primarily gated by ligand binding, the current flow through the ion channel is voltage-dependent. Specifically located on the receptor, extracellular magnesium (Mg 2+ ) and zinc (Zn 2+ ) ions can bind and prevent other cations from flowing through the open ion channel.

A voltage-dependent flow of predominantly calcium (Ca 2+ ), sodium (Na + ), and potassium (K + ) ions into and out of the cell is made possible by the depolarization of the cell, which displaces and repels the Mg 2+ and Zn 2+ ions from the pore. Ca 2+ flux through NMDA receptors in particular is thought to be critical in synaptic plasticity, a cellular mechanism for learning and memory, due to proteins which bind to and are activated by Ca 2+ ions.

Activity of the NMDA receptor is blocked by many psychoactive drugs such as phencyclidine (PCP), alcohol (ethanol) and dextromethorphan (DXM). The anaesthetic and analgesic effects of the drugs ketamine and nitrous oxide are also partially due to their effects at blocking NMDA receptor activity.

In contrast, overactivation of NMDAR by NMDA agonists increases the cytosolic concentrations of calcium and zinc, which significantly contributes to neural death, an effect known to be prevented by cannabinoids, mediated by activation of the CB 1 receptor, which leads HINT1 protein to counteract the toxic effects of NMDAR-mediated NO production and zinc release. As well as preventing methamphetamine-induced neurotoxicity via inhibition of nitric oxide synthase (nNOS) expression and astrocyte activation, it is seen to reduce methamphetamine-induced brain damage through CB1-dependent and independent mechanisms, respectively, and inhibition of methamphetamine-induced astrogliosis is likely to occur through a CB 2 receptor dependent mechanism for THC.

Since 1989, memantine has been recognized to be an uncompetitive antagonist of the NMDA receptor, entering the channel of the receptor after it has been activated and thereby blocking the flow of ions. Overactivation of the receptor, causing excessive influx of Ca 2+ can lead to excitotoxicity which is implied to be involved in some neurodegenerative disorders.

Blocking of NMDA receptors could therefore, in theory, be useful in treating such diseases. However, hypofunction of NMDA receptors (due to glutathione deficiency or other causes) may be involved in impairment of synaptic plasticity and could have other negative repercussions.

The main problem with the utilization of NMDA receptor antagonists for neuroprotection is that the physiological actions of the NMDA receptor are essential for normal neuronal function. To be clinically useful NMDA antagonists need to block excessive activation without interfering with normal functions. Memantine has this property.

GluN1

There are eight variants of the GluN1 subunit produced by alternative splicing of GRIN1: GluN1-1a, GluN1-1b; GluN1-1a is the most abundantly expressed form. GluN1-2a, GluN1-2b; GluN1-3a, GluN1-3b; GluN1-4a, GluN1-4b;

GluN2

While a single GluN2 subunit is found in invertebrate organisms, four distinct isoforms of the GluN2 subunit are expressed in vertebrates and are referred to with the nomenclature GluN2A through GluN2D (encoded by GRIN2A, GRIN2B, GRIN2C, GRIN2D). Strong evidence shows that the genes encoding the GluN2 subunits in vertebrates have undergone at least two rounds of gene duplication. They contain the binding-site for glutamate.

More importantly, each GluN2 subunit has a different intracellular C-terminal domain that can interact with different sets of signaling molecules. Unlike GluN1 subunits, GluN2 subunits are expressed differentially across various cell types and developmental timepoints and control the electrophysiological properties of the NMDA receptor.

In classic circuits, GluN2B is mainly present in immature neurons and in extrasynaptic locations such as growth cones, and contains the binding-site for the selective inhibitor ifenprodil. However, in pyramidal cell synapses in the newly evolved primate dorsolateral prefrontal cortex, GluN2B are exclusively within the postsynaptic density, and mediate higher cognitive operations such as working memory.

This is consistent with the expansion in GluN2B actions and expression across the cortical hierarchy in monkeys and humans and across primate cortex evolution.

GluN2B to GluN2A switch

While GluN2B is predominant in the early postnatal brain, the number of GluN2A subunits increases during early development; eventually, GluN2A subunits become more numerous than GluN2B. This is called the GluN2B-GluN2A developmental switch, and is notable because of the different kinetics each GluN2 subunit contributes to receptor function. For instance, greater ratios of the GluN2B subunit leads to NMDA receptors which remain open longer compared to those with more GluN2A. This may in part account for greater memory abilities in the immediate postnatal period compared to late in life, which is the principle behind genetically altered 'doogie mice'.

The detailed time course of this switch in the human cerebellum has been estimated using expression microarray and RNA seq and is shown in the figure on the right. There are three hypothetical models to describe this switch mechanism: Increase in synaptic GluN2A along with decrease in GluN2B Extrasynaptic displacement of GluN2B away from the synapse with increase in GluN2A Increase of GluN2A diluting the number of GluN2B without the decrease of the latter.

The GluN2B and GluN2A subunits also have differential roles in mediating excitotoxic neuronal death. The developmental switch in subunit composition is thought to explain the developmental changes in NMDA neurotoxicity.

Homozygous disruption of the gene for GluN2B in mice causes perinatal lethality, whereas disruption of the GluN2A gene produces viable mice, although with impaired hippocampal plasticity. One study suggests that reelin may play a role in the NMDA receptor maturation by increasing the GluN2B subunit mobility.

GluN2B to GluN2C switch

Granule cell precursors (GCPs) of the cerebellum, after undergoing symmetric cell division in the external granule-cell layer (EGL), migrate into the internal granule-cell layer (IGL) where they down-regulate GluN2B and activate GluN2C, a process that is independent of neuregulin beta signaling through ErbB2 and ErbB4 receptors.

Role in excitotoxicity

NMDA receptors have been implicated by a number of studies to be strongly involved with excitotoxicity. Because NMDA receptors play an important role in the health and function of neurons, there has been much discussion on how these receptors can affect both cell survival and cell death.

Recent evidence supports the hypothesis that overstimulation of extrasynaptic NMDA receptors has more to do with excitotoxicity than stimulation of their synaptic counterparts. In addition, while stimulation of extrasynaptic NMDA receptors appear to contribute to cell death, there is evidence to suggest that stimulation of synaptic NMDA receptors contributes to the health and longevity of the cell.

There is ample evidence to support the dual nature of NMDA receptors based on location, and the hypothesis explaining the two differing mechanisms is known as the "localization hypothesis".

Differing cascade pathways

In order to support the localization hypothesis, it would be necessary to show differing cellular signaling pathways are activated by NMDA receptors based on its location within the cell membrane. Experiments have been designed to stimulate either synaptic or non-synaptic NMDA receptors exclusively.

These types of experiments have shown that different pathways are being activated or regulated depending on the location of the signal origin. Many of these pathways use the same protein signals, but are regulated oppositely by NMDARs depending on its location.

For example, synaptic NMDA excitation caused a decrease in the intracellular concentration of p38 mitogen-activated protein kinase (p38MAPK). Extrasynaptic stimulation NMDARs regulated p38MAPK in the opposite fashion, causing an increase in intracellular concentration.

Experiments of this type have since been repeated with the results indicating these differences stretch across many pathways linked to cell survival and excitotoxicity. Two specific proteins have been identified as a major pathway responsible for these different cellular responses ERK1/2, and Jacob. ERK1/2 is responsible for phosphorylation of Jacob when excited by synaptic NMDARs.

This information is then transported to the nucleus. Phosphorylation of Jacob does not take place with extrasynaptic NMDA stimulation. This allows the transcription factors in the nucleus to respond differently based in the phosphorylation state of Jacob.

Neural plasticity

NMDA receptors (NMDARs) critically influence the induction of synaptic plasticity. NMDARs trigger both long-term potentiation (LTP) and long-term depression (LTD) via fast synaptic transmission. Experimental data suggest that extrasynaptic NMDA receptors inhibit LTP while producing LTD. Inhibition of LTP can be prevented with the introduction of a NMDA antagonist.

A theta burst stimulation that usually induces LTP with synaptic NMDARs, when applied selectively to extrasynaptic NMDARs produces a LTD. Experimentation also indicates that extrasynaptic activity is not required for the formation of LTP. In addition, both synaptic and extrasynaptic activity are involved in expressing a full LTD.

Role of differing subunits

Another factor that seems to affect NMDAR induced toxicity is the observed variation in subunit makeup. NMDA receptors are heterotetramers with two GluN1 subunits and two variable subunits. Two of these variable subunits, GluN2A and GluN2B, have been shown to preferentially lead to cell survival and cell death cascades respectively.

Although both subunits are found in synaptic and extrasynaptic NMDARs there is some evidence to suggest that the GluN2B subunit occurs more frequently in extrasynaptic receptors. This observation could help explain the dualistic role that NMDA receptors play in excitotoxicity. t-NMDA receptors have been implicated in excitotoxicity-mediated death of neurons in temporal lobe epilepsy.

Despite the compelling evidence and the relative simplicity of these two theories working in tandem, there is still disagreement about the significance of these claims. Some problems in proving these theories arise with the difficulty of using pharmacological means to determine the subtypes of specific NMDARs.

In addition, the theory of subunit variation does not explain how this effect might predominate, as it is widely held that the most common tetramer, made from two GluN1 subunits and one of each subunit GluN2A and GluN2B, makes up a high percentage of the NMDARs. The subunit composition of t-NMDA receptors has recently been visualized in brain tissue.

Excitotoxicity in a clinical setting

Excitotoxicity has been thought to play a role in the degenerative properties of neurodegenerative conditions since the late 1950s. NMDA receptors seem to play an important role in many of these degenerative diseases affecting the brain. Most notably, excitotoxic events involving NMDA receptors have been linked to Alzheimer's disease and Huntington's disease, as well as with other medical conditions such as strokes and epilepsy.

Treating these conditions with one of the many known NMDA receptor antagonists, however, leads to a variety of unwanted side effects, some of which can be severe. These side effects are, in part, observed because the NMDA receptors do not just signal for cell death but also play an important role in its vitality.

Treatment for these conditions might be found in blocking NMDA receptors not found at the synapse. One class of excitotoxicity in disease includes gain-of-function mutations in GRIN2B and GRIN1 associated with cortical malformations, such as polymicrogyria.

D-serine, an antagonist/inverse co-agonist of t-NMDA receptors, which is made in the brain, has been shown to mitigate neuron loss in an animal model of temporal lobe epilepsy.

Agonists

(glutamate), the major endogenous agonist of the main site of the NMDAR , the major endogenous agonist of the glycine co-agonist site of the NMDAR Activation of NMDA receptors requires binding of glutamate or aspartate (aspartate does not stimulate the receptors as strongly). In addition, NMDARs also require the binding of the co-agonist glycine for the efficient opening of the ion channel, which is a part of this receptor.

D -Serine has also been found to co-agonize the NMDA receptor with even greater potency than glycine. It is produced by serine racemase, and is enriched in the same areas as NMDA receptors. Removal of D -serine can block NMDA-mediated excitatory neurotransmission in many areas.

Recently, it has been shown that D -serine can be released both by neurons and astrocytes to regulate NMDA receptors. Note that D-serine has also been shown to work as an antagonist / inverse co-agonist for t-NMDA receptors. NMDA receptor (NMDAR)-mediated currents are directly related to membrane depolarization.

NMDA agonists therefore exhibit fast Mg 2+ unbinding kinetics, increasing channel open probability with depolarization. This property is fundamental to the role of the NMDA receptor in memory and learning, and it has been suggested that this channel is a biochemical substrate of Hebbian learning, where it can act as a coincidence detector for membrane depolarization and synaptic transmission.

Examples

Some known NMDA receptor agonists include: Amino acids and amino acid derivatives Glutamic acid (glutamate) – endogenous glutamate site agonist Aspartic acid (aspartate) ( D -aspartic acid, L -aspartic acid) – endogenous glutamate site agonist N-Methyl-D-aspartic acid - endogenous glutamate site agonist and namesake of the receptor Tetrazolylglycine – synthetic glutamate site agonist Homocysteic acid – endogenous glutamate site agonist Ibotenic acid – naturally occurring glutamate site agonist found in Amanita muscaria Quinolinic acid (quinolinate) – endogenous glutamate site agonist Glycine – endogenous glycine site agonist Alanine ( D -alanine, L -alanine) – endogenous glycine site agonist Milacemide – synthetic glycine site agonist; prodrug of glycine Sarcosine (monomethylglycine) – endogenous glycine site agonist Serine ( D -serine, L -serine) – endogenous glycine site agonist β-Alanine – endogenous glycine site agonist Positive allosteric modulators Cerebrosterol – endogenous weak positive allosteric modulator Cholesterol – endogenous weak positive allosteric modulator Dehydroepiandrosterone (DHEA) – endogenous weak positive allosteric modulator Dehydroepiandrosterone sulfate (DHEA-S) – endogenous weak positive allosteric modulator Nebostinel (neboglamine) – synthetic positive allosteric modulator of the glycine site Pregnenolone sulfate – endogenous weak positive allosteric modulator Polyamines Spermidine – endogenous polyamine site agonist Spermine – endogenous polyamine site agonist

Partial agonists

(NMDA), a synthetic partial agonist of the main site of the NMDAR N-Methyl- D -aspartic acid (NMDA), which the NMDA receptor was named after, is a partial agonist of the active or glutamate recognition site. 3,5-Dibromo- L -phenylalanine, a naturally occurring halogenated derivative of L -phenylalanine, is a weak partial NMDA receptor agonist acting on the glycine site.

3,5-Dibromo- L -phenylalanine has been proposed a novel therapeutic drug candidate for treatment of neuropsychiatric disorders and diseases such as schizophrenia, and neurological disorders such as ischemic stroke and epileptic seizures. Other partial agonists of the NMDA receptor acting on novel sites such as rapastinel (GLYX-13) and apimostinel (NRX-1074) are now viewed for the development of new drugs with antidepressant and analgesic effects without obvious psychotomimetic activities.

Examples

Aminocyclopropanecarboxylic acid (ACC) – synthetic glycine site partial agonist Cycloserine ( D -cycloserine) – naturally occurring glycine site partial agonist found in Streptomyces orchidaceus HA-966 and L-687,414 – synthetic glycine site weak partial agonists Homoquinolinic acid – synthetic glutamate site partial agonist N-Methyl- D -aspartic acid (NMDA) – synthetic glutamate site partial agonist Positive allosteric modulators include: Zelquistinel (GATE-251) – synthetic novel site partial agonist Apimostinel (GATE-202) – synthetic novel site partial agonist Rapastinel (GLYX-13) – synthetic novel site partial agonist

Antagonists

, a synthetic general anesthetic and one of the best-known NMDAR antagonists Antagonists of the NMDA receptor are used as anesthetics for animals and sometimes humans, and are often used as recreational drugs due to their hallucinogenic properties, in addition to their unique effects at elevated dosages such as dissociation. When certain NMDA receptor antagonists are given to rodents in large doses, they can cause a form of brain damage called Olney's lesions.

NMDA receptor antagonists that have been shown to induce Olney's lesions include ketamine and phencyclidine, as well as some NMDA receptor antagonists used only in research environments. So far, the published research on Olney's lesions is inconclusive in its occurrence upon human or monkey brain tissues with respect to an increase in the presence of NMDA receptor antagonists.

Most NMDAR antagonists are uncompetitive or noncompetitive blockers of the channel pore or are antagonists of the glycine co-regulatory site rather than antagonists of the active/glutamate site.

Examples

Common agents in which NMDA receptor antagonism is the primary or a major mechanism of action: 4-Chlorokynurenine (AV-101) – glycine site antagonist; prodrug of 7-chlorokynurenic acid 7-Chlorokynurenic acid – glycine site antagonist Agmatine – endogenous polyamine site antagonist Argiotoxin-636 – naturally occurring dizocilpine or related site antagonist found in Argiope venom AP5 – glutamate site antagonist AP7 – glutamate site antagonist CGP-37849 – glutamate site antagonist D-serine - t-NMDA receptor antagonist / inverse co-agonist Delucemine (NPS-1506) – dizocilpine or related site antagonist; derived from argiotoxin-636 Dextromethorphan (DXM) – dizocilpine site antagonist; prodrug of dextrorphan Dextrorphan (DXO) – dizocilpine site antagonist Dexanabinol – dizocilpine-related site antagonist Diethyl ether – unknown site antagonist Diphenidine – dizocilpine site antagonist Dizocilpine (MK-801) – dizocilpine site antagonist Eliprodil – ifenprodil site antagonist Esketamine – dizocilpine site antagonist Hodgkinsine – undefined site antagonist Ifenprodil – ifenprodil site antagonist Kaitocephalin – naturally occurring glutamate site antagonist found in Eupenicillium shearii Ketamine – dizocilpine site antagonist Kynurenic acid – endogenous glycine site antagonist Lanicemine – low-trapping dizocilpine site antagonist LY-235959 – glutamate site antagonist Memantine – low-trapping dizocilpine site antagonist Methoxetamine – dizocilpine site antagonist Midafotel – glutamate site antagonist Nitrous oxide (N 2 O) – undefined site antagonist PEAQX – glutamate site antagonist Perzinfotel – glutamate site antagonist Phencyclidine (PCP) – dizocilpine site antagonist Phenylalanine - a naturally occurring amino acid, glycine site antagonist Psychotridine – undefined site antagonist Selfotel – glutamate site antagonist Tiletamine – dizocilpine site antagonist Traxoprodil – ifenprodil site antagonist Xenon – unknown site antagonist Some common agents in which weak NMDA receptor antagonism is a secondary or additional action include: Amantadine – an antiviral and antiparkinsonian drug; low-trapping dizocilpine site antagonist Atomoxetine – a norepinephrine reuptake inhibitor used to treat Dextropropoxyphene – an opioid analgesic Ethanol (alcohol) – a euphoriant, sedative, and anxiolytic used recreationally; unknown site antagonist Guaifenesin – an expectorant Huperzine A – a naturally occurring acetylcholinesterase inhibitor and potential antidementia agent Ibogaine – a naturally occurring hallucinogen and antiaddictive agent Ketobemidone – an opioid analgesic Methadone – an opioid analgesic Minocycline – an antibiotic Tramadol – an atypical opioid analgesic and serotonin releasing agent Negative allosteric modulators include: 25-Hydroxycholesterol – endogenous weak negative allosteric modulator Conantokins – naturally occurring negative allosteric modulators of the polyamine site found in Conus geographus

The NMDA receptor is modulated by a number of endogenous and exogenous compounds: Aminoglycosides have been shown to have a similar effect to polyamines, and this may explain their neurotoxic effect. CDK5 regulates the amount of NR2B-containing NMDA receptors on the synaptic membrane, thus affecting synaptic plasticity.

Polyamines do not directly activate NMDA receptors, but instead act to potentiate or inhibit glutamate-mediated responses. Reelin modulates NMDA function through Src family kinases and DAB1. significantly enhancing LTP in the hippocampus. Src kinase enhances NMDA receptor currents.

Na + , K + and Ca 2+ not only pass through the NMDA receptor channel but also modulate the activity of NMDA receptors. Zn 2+ and Cu 2+ generally block NMDA current activity in a noncompetitive and a voltage-independent manner. However zinc may potentiate or inhibit the current depending on the neural activity.

Pb 2+ is a potent NMDAR antagonist. Presynaptic deficits resulting from Pb 2+ exposure during synaptogenesis are mediated by disruption of NMDAR-dependent BDNF signaling.

Proteins of the major histocompatibility complex class I are endogenous negative regulators of NMDAR-mediated currents in the adult hippocampus, and are required for appropriate NMDAR-induced changes in AMPAR trafficking and NMDAR-dependent synaptic plasticity and learning and memory. The activity of NMDA receptors is also strikingly sensitive to the changes in pH, and partially inhibited by the ambient concentration of H + under physiological conditions.

The level of inhibition by H + is greatly reduced in receptors containing the NR1a subtype, which contains the positively charged insert Exon 5. The effect of this insert may be mimicked by positively charged polyamines and aminoglycosides, explaining their mode of action.

NMDA receptor function is also strongly regulated by chemical reduction and oxidation, via the so-called "redox modulatory site." Through this site, reductants dramatically enhance NMDA channel activity, whereas oxidants either reverse the effects of reductants or depress native responses.

It is generally believed that NMDA receptors are modulated by endogenous redox agents such as glutathione, lipoic acid, and the essential nutrient pyrroloquinoline quinone. Several derivatives of nitromemantine have been synthesized in order to perform a detailed structure activity relationship (SAR) of these novel drugs.

One class, containing a nitro (NO 2 ) group opposite to the bridgehead amine (NH 2 ), showed a promising outcome. Nitromemantine utilizes the memantine binding site on the NMDA receptor to target the NO x (X= 1 or 2) group for interaction with the S- nitrosylation/redox site external to the memantine binding site.

Lengthening the side chains of memantine compensates for the worse drug affinity in the channel associated with the addition of the –ONO 2 group.

Receptor modulation

The NMDA receptor is a non-specific cation channel that can allow the passage of Ca 2+ and Na + into the cell and K + out of the cell. The excitatory postsynaptic potential (EPSP) produced by activation of an NMDA receptor increases the concentration of Ca 2+ in the cell. The Ca 2+ can in turn function as a second messenger in various signaling pathways.

However, the NMDA receptor cation channel is blocked by Mg 2+ at resting membrane potential. Magnesium unblock is not instantaneous; to unblock all available channels, the postsynaptic cell must be depolarized for a sufficiently long period of time (in the scale of milliseconds). Therefore, the NMDA receptor functions as a "molecular coincidence detector".

Its ion channel opens only when the following two conditions are met: glutamate is bound to the receptor, and the postsynaptic cell is depolarized (which removes the Mg 2+ blocking the channel). This property of the NMDA receptor explains many aspects of long-term potentiation (LTP) and synaptic plasticity.

In a resting-membrane potential, the NMDA receptor pore is opened allowing for an influx of external magnesium ions binding to prevent further ion permeation. External magnesium ions are in a millimolar range while intracellular magnesium ions are at a micromolar range to result in negative membrane potential.

NMDA receptors are modulated by a number of endogenous and exogenous compounds and play a key role in a wide range of physiological (e.g., memory) and pathological processes (e.g., excitotoxicity). Magnesium works to potentiate NMDA-induced responses at positive membrane potentials while blocking the NMDA channel.

The use of calcium, potassium, and sodium are used to modulate the activity of NMDARs passing through the NMDA membrane. Changes in H + concentration can partially inhibit the activity of NMDA receptors in different physiological conditions.

Clinical significance

NMDAR dysfunction leads to several diseases. Mutations in Grin genes coding for NMDAR subunits result in GRIN disorders, a group of neurodevelopmental disorders characterised by developmental delay, intellectual disability, and epileptic seizures.

Aberrant NMDAR activation may be a cause of cochlear tinnitus, so cochlear NMDARs are a target of research to find pharmacological solutions to treat tinnitus. NMDARs are also associated with a rare autoimmune disease, anti-NMDA receptor encephalitis (also known as NMDAR encephalitis ), that usually occurs due to cross-reactivity of antibodies produced by the immune system against ectopic brain tissues, such as those found in teratoma.

These are known as anti-glutamate receptor antibodies. NMDAR-targeting compounds are under investigation for the treatment of mood disorders.

For example, ketamine, esketamine (JNJ-54135419), rapastinel (GLYX-13), apimostinel (NRX-1074), zelquistinel (AGN-241751), 4-chlorokynurenine (AV-101), and rislenemdaz (CERC-301, MK-0657), are under development for the treatment of mood disorders including major depressive disorder and treatment-resistant depression. In addition, ketamine is already employed for this purpose as an off-label therapy in some clinics.

Research also suggests that tianeptine produces antidepressant effects, through indirect alteration and inhibition of glutamate receptor activity and release of , in turn affecting neural plasticity. Tianeptine also acts on the NMDA and AMPA receptors.

In animal models, tianeptine inhibits the pathological stress-induced changes in glutamatergic neurotransmission in the amygdala and hippocampus. NMDAR-targeting compounds may also be useful for treating schizophrenia.

Compared to dopaminergic stimulants like methamphetamine, the NMDAR antagonist phencyclidine can produce a wider range of symptoms that resemble schizophrenia in healthy volunteers, in what has led to the glutamate hypothesis of schizophrenia. Experiments in which rodents are treated with NMDA receptor antagonist are today the most common model when it comes to testing of novel schizophrenia therapies or exploring the exact mechanism of drugs already approved for treatment of schizophrenia.

Memantine, a low-trapping NMDAR antagonist, is approved in the United States and Europe for the treatment of moderate-to-severe Alzheimer's disease, and has now received a limited recommendation by the UK's National Institute for Health and Care Excellence for patients who fail other treatment options. NMDAR antagonists, for instance eliprodil, gavestinel, licostinel, and selfotel have been extensively investigated for the treatment of excitotoxicity-mediated neurotoxicity in situations like ischemic stroke and traumatic brain injury, but were unsuccessful in clinical trials used in small doses to avoid sedation, but NMDAR antagonists can block Spreading Depolarizations in animals and in patients with brain injury.

This use has not been tested in clinical trials yet. NMDAR antagonists like ketamine, esketamine, tiletamine, phencyclidine, nitrous oxide, and xenon are used as general anesthetics. These and similar drugs like dextromethorphan and methoxetamine also produce dissociative, hallucinogenic, and euphoriant effects and are used as recreational drugs.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378375701 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

19 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.